Results 201 to 210 of about 47,580 (341)

A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F. [PDF]

J Biol Chem
Tian H, Fung CP, Burman L, Chong YE, Liu C, Geng Y, Yang L, Chow MW, Zhang Y, Ho KWH, Zhu G, Wu Z, Yang XL, Xu Z, Nangle LA.   +14 more
europepmc   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency

, 2019
Linlin Wang, Sayed Shahabuddin Hoseini, Hong Xu, Vladimir Ponomarev, Nai‐Kong V. Cheung   +4 more
openalex   +2 more sources

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. [PDF]

J Immunother Cancer
Nan L, Chen L, Huang W, Peng S, Wang C, Liao H, Wang Y, Cui Z, Lv Y, Wang X, Luo Y, Tsun A, Miao X, Zhang J.   +13 more
europepmc   +1 more source

Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive cohort.
A. Coste, S. Godet, S. Manier, J. R. Eveillard, C. Croizier, C. Mariette, C. Breal, H. Manjra, C. Touzeau, M. Mohty, R. Belkhir, A. Bobin, A. Lévêque, B. Cherel, L. Montes, F. Orsini‐Piocelle, L. Frenzel, D. Robu, E. Chalayer, S. Harel, L. Vincent, L. Bauschert, A. Dony, R. Tabrizi, P. Moreau, C. Hulin, A. Perrot   +26 more
wiley   +1 more source

Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]

Transpl Infect Dis
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH.   +5 more
europepmc   +1 more source

1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01

Byoung Chul Cho, J.T.J.N. Hiltermann, Hiroki Izumi, Mariana Brandão, S.C.S. Oliveira, Pongwut Danchaivijitr, Enriqueta Felip, Gwo Fuang Ho, K. Leventakos, Yongsheng Li, S. Sugawara, P-J. Voon, Els Wauters, T-Y. Yang, Tatsuya Yoshida, H. Chen, Ikbel Achour, Steve Colebrook, N. Liu, Yulei Wang   +19 more
openalex   +2 more sources

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade [PDF]

Przemysław Bielski, Jan Barczyński, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec, Tad A. Holak, Tomasz Sitar   +9 more
openalex   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source